Association between brain-derived neurotrophic factor genetic polymorphism Val66Met and susceptibility to bipolar disorder: a meta-analysis by unknown
Wang et al. BMC Psychiatry  (2014) 14:366 
DOI 10.1186/s12888-014-0366-9RESEARCH ARTICLE Open AccessAssociation between brain-derived neurotrophic
factor genetic polymorphism Val66Met and
susceptibility to bipolar disorder: a meta-analysis
Zuowei Wang1,4*, Zezhi Li2, Keming Gao3 and Yiru Fang4*Abstract
Background: In view of previous conflicting findings, this meta-analysis was performed to comprehensively determine
the overall strength of associations between brain-derived neurotrophic factor (BDNF) genetic polymorphism Val66Met
and susceptibility to bipolar disorders (BPD).
Methods: Literatures published and cited in Pubmed and Wanfang Data was searched with terms of ‘Val66Met’,
‘G196A’, ‘rs6265’, ‘BDNF’, ‘association’, and ‘bipolar disorder’ up to March 2014. All original case–control association
studies were meta-analyzed with a pooled OR to estimate the risk and 95% confidence interval (CI) to reflect the
magnitude of variance.
Results: Twenty-one case–control association studies met our criteria for the meta-analysis. Overall, there was no significant
difference in allelic distribution of Val66Met polymorphism between patients and controls with a pooled OR = 1.03 (95% CI
0.98, 1.08) although there was a trend towards association between Val66Met polymorphism and BPD in Caucasians with
an OR of 1.08 (95% CI 1.00, 1.16). However, subgroup analyses showed that there was a significant association of Val allele
with decreased disease susceptibility for bipolar disorder type II with a pooled OR of 0.88 (95% CI 0.78, 0.99).
Conclusions: There is no compelling evidence to supportVal66Met polymorphism in BDNF gene playing an important role
in the susceptibility to BPD across different ethnicities.
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Bipolar disorders (BPD) are chronic, recurrent, debilitat-
ing disorders with high lifetime prevalence and significant
disease burden across different populations [1-3]. How-
ever, recent advances in pharmacological treatment for
BPD remained quite modest. The treatment of bipolar de-
pression is still a major challenge [4,5]. Moreover, BPD is
frequently unrecognized and misdiagnosed, particularly in
patients presenting with their first-episode of depression.
These patients are often treated with inappropriate and
costly regimens [6-9]. Thus, there is an urgent need to
understand the pathophysiology of BPD in order to de-
velop earlier diagnoses and more effective treatments [10].* Correspondence: wzwhk@163.com; yirufang@aliyun.com
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unless otherwise stated.Family, twins and epidemiological studies unequivocally
demonstrate that BPD is a highly heritable disease with a
heritability of more than 85%, and involves the interaction
of multiple genes or more complex genetic mechanisms
[11-13]. To date, association studies support a possible
role for several candidate genes in BPD, including brain-
derived neurotrophic factor (BDNF), but consistent direc-
tion of effects and alleles have not been established [14].
These inconsistent findings from previous genetic associ-
ation studies may be related to variation in ascertainment,
phenotype definition and control selection, limited power
and possibly confounded by ethnic heterogeneity and
population substructure [10,15].
The hypothesis of neuronal plasticity involved in mood
disorders has been supported by the use of antidepres-
sants and mood stabilizers, e.g. lithium and valproate, in-
ducing the expression of neurotrophins (e.g. BDNF) and
synaptic changes [16,17]. Moreover, BDNF gene has beenThis is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
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Position 196 in exon 5 of the BDNF gene contains a G to A
transition (dbSNP: rs6265) that results in an amino acid
substitution (valine to methionine) at codon 66 in the pre-
cursor BDNF peptide sequence [19]. This change results in
BDNF functional polymorphisms in this region as Val66Val,
Val66Met, and Met66Met. Two previous family-based asso-
ciation studies found that this functional polymorphism
Val66Met was significantly associated with the susceptibility
to BPD [20,21]. Following these two reports, a large num-
ber of association studies between BDNF gene polymor-
phisms and BPD have been published. Most of them
specifically focused on the Val66Met polymorphism, but
yielded conflicting results [10,15,22]. In view of the conflict-
ing results, a meta-analysis on all original case–control as-
sociation studies was performed to comprehensively
determine the overall strength of associations between BPD
and Val66Met polymorphism.Methods
Literature search
Studies included in the analysis were searched from two
databases: Pubmed (http://www.ncbi.nlm.nih.gov/pubmed/)
and Wanfang Data (http://www.wanfangdata.com/), with
the keywords ‘Val66Met’, ‘G196A’, ‘rs6265’, ‘BDNF’, ‘associ-
ation’, and ‘bipolar disorder’ in varying combinations. The
retrieved abstracts were used to identify studies that exam-
ined the allelic association between the Val66Met poly-
morphism of BDNF and bipolar disorder. Bibliographies or
citations from retrieved articles were also cross-referenced
as well. The searched period was from the first data available
in each database up to March 2014. Two independent au-
thors extracted the following data from each eligible study:
last name of the first author, year of publication, ethnicity,
sample sizes and allele frequencies of cases and controls, etc.
Discrepancies were resolved by mutual consent.
All eligible studies were determined against the
following inclusion criteria: (i) published in a peer-
reviewed journal; (ii) presented original data; (iii)
provided either allele frequency of Val(G)/Met(A), or
genotypes (Val/Val, Val/Met, Met/ Met) in both BPD
patients and healthy controls; (iv) enrolled more than
100 subjects in both patients group and controls group;
and (v) designed as a case–control study. Both family-
based studies and genome-wide association studies were
excluded in this research. Duplications were deleted, as
well as studies that reported all or part of their data pre-
viously. The authors of studies were contacted for add-
itional information (e.g. allele or genotype frequencies
or characteristics of the samples) if there was uncer-
tainty about whether their data met our inclusion–ex-
clusion criteria, or if we needed additional data which
were not contained in the original report.Statistical analyses
Data were classified by diagnostic category (case or control)
and allele (Val or Met), and Val was assigned as the risk al-
lele. Meta-analysis was performed similar to that described
previously [22]. The pooled OR was calculated according to
the methods of DerSimonian [23], and its 95% confidence
interval (CI) was constructed using Woolf ’s method [24].
The Cochran chi-square-based Q statistical test was per-
formed to assess the heterogeneity of ORs, and the signifi-
cance of the pooled OR was determined by the z-test. If the
result of the heterogeneity test was p ≥ 0.05, ORs were
pooled according to the fixed-effects model (Mantel-
Haenszel methods); otherwise, the random-effects model
was used. All statistical analyses were conducted using
Review Manager Version 5.2 (RevMan 5.2) [25]. A sensi-
tivity analysis of one-study removed strategy was used to
evaluate whether or not the results are being driven by
any one specific study, and a funnel plot was used to de-
tect whether or not there is evidence of publication bias.
Statistical tests were two-tailed, and the significance level
was set at P < 0.05, unless stated otherwise.Results
The process of identifying studied included in this meta-
analysis is shown in Figure 1. Twenty-one case–control as-
sociation studies met our criteria for the meta-analysis
(Table 1). Data from four studies [26-29] were excluded
due to the partial overlap with a larger sample size case–
control study [30], and data from six studies were excluded
due to less than 100 subjects in either patient group or con-
trol group [31-36]. Additionally, the case–control sample
from a genome-wide association study was also excluded
from current meta-analysis [37].
Overall, the data from 7219 BPD cases and 9832 healthy
controls were analyzed. The mean genotype distribution in
Caucasian and Oriental population was presented in
Table 2. There was no significant difference in allelic distri-
bution of Val66Met polymorphism between patients and
controls. The pooled OR was 1.03 (95% CI: 0.98-1.08, Z =
1.00, P = 0.32) (Figure 2). Similarly, there was also no sig-
nificant difference in allelic distribution of Val66Met poly-
morphism between patients and controls in Oriental
population, with a pooled OR of 0.96 (95% CI: 0.89-1.05,
Z = 0.82, P = 0.41) for Han Chinese population, 0.99
(95% CI: 0.85-1.15, Z = 0.12, P = 0.90) for Japanese popula-
tion, and 1.06 (95% CI: 0.89-1.25, Z = 0.67, P = 0.50) for
Korean population, respectively (Figure 2). However, there
was a trend towards significant difference in Caucasian
population with a pooled OR of 1.08 (95% CI: 1.00-1.16,
Z = 1.97, P = 0.05) (Figure 2). The sensitivity analysis
showed that the results were not being driven by any one
specific study, and the funnel plot did not detect there was
evidence of publication bias (Figure 3).
30 potential English-language articles
from Pubmed
2 potential Chinese-language articles
form Wanfang Data
11 articles excluded
- 4 partial results from a larger
sample size study
- 6 less than 100 subjects in either
patient or control group
- 1 genome-wide association study
19 studies in English and 2 studies in Chinese included for meta-analysis
Figure 1 Identification of studies for meta-analysis.
Table 1 Descriptive characteristics of included association studies between BDNF gene Val66Met polymorphism and
bipolar disorders
Study Year Ancestry Diagnostic criteria Patient’s phenotype Cases Controls Case Val Controls Val
Hong et al. [38] 2003 Han Chinese DSM-IV BPD 108 392 118 406
Nakata et al. [39] 2003 Japanese DSM-IV BPI + BPII 130 190 152 220
Kunugi et al. [40] 2004 Japanese DSM-IV BPI + BPII 519 588 615 702
Oswald et al. [41] 2004 Caucasian DSM-IV BPAD 108 158 166 247
Skibinska et al. [42] 2004 Caucasian DSM-IV BPAD 352 375 588 613
Lohoff et al. [43] 2005 Caucasian DSM-IV BPI 621 998 1020 1576
Neves-Pereira et al. [44] 2005 Caucasian DSM-IV BPAD 263 350 417 547
Schumacher et al. [45] 2005 Caucasian DSM-IV BPAD 281 1097 456 1778
Green et al. [46] 2006 Caucasian DSM-IV BPI + BPII + Rapid-cycling BPD 1093 2100 1808 3404
Liu et al. [47] 2007 Han Chinese ICD-10 BPAD 100 100 114 99
Tramontina et al. [48] 2007 Caucasian DSM-IV BPI 114 137 183 230
Kim et al. [49] 2008 Korean DSM-IV BPD 169 251 186 268
Tang et al. [50] 2008 Han Chinese DSM-IV BPD 197 208 238 235
Vincze et al. [51] 2008 Caucasian DSM-IV BPD 336 313 532 473
Ye et al. [52] 2009 Han Chinese DSM-IV BPD 222 357 217 367
Hosang et al. [53] 2010 Caucasian ICD-10 BPD 488 598 780 983
Xu et al. [54] 2010 Han Chinese DSM-IV BPI + BPII 498 501 525 546
Min et al. [55] 2012 Korean DSM-IV BPD 184 214 222 245
Wang et al. [56] 2012 Han Chinese DSM-IV BPI + BPII 337 386 341 436
Chang et al. [30] 2013 Han Chinese DSM-IV BPI + BPII 967 349 962 361
Pae et al. [57] 2012 Korean DSM-IV BPD 132 170 150 197
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Table 2 Pooled genotype distribution of Val66Met polymorphism in Caucasian and Oriental population
Population BPD patients Health controls
Val/Val Val/Met Met/Met Val/Val Val/Met Met/Met
Caucasian 0.654 0.320 0.026 0.642 0.324 0.034
Oriental 0.296 0.486 0.218 0.311 0.489 0.200
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studies made a distinction for clinical phenotypes between
bipolar I disorder (BP I) and bipolar II disorder (BP II), and
two other studies only recruited BP I patients (Table 3). A
further meta-analysis of the data from the aforementioned
eight studies did not find a significant difference in allelic
distribution of Val66Met polymorphism between BP I
patients and healthy controls with a pooled OR of 1.00
(95% CI: 0.93-1.08, Z = 0.04, P = 0.97) (Figure 4). However,
there was a significant difference in allelic distribution of
Val66Met polymorphism between BP II patients and
healthy controls with a pooled OR of 0.88 (95% CI: 0.78-Figure 2 Forest plot of association between BDNF gene Val66Met po0.99, Z = 2.20, P = 0.03) (Figure 4). A post-hoc analysis did
not find a significant difference in allelic distribution of
Val66Met polymorphism between BP I patients and BP II
patients with a pooled OR of 1.10 (95% CI: 0.98-1.25, Z =
1.58, P = 0.12) (Figure 5).
Discussion
With a total of 7,219 patients and 9,832 control cases, our
meta-analysis included an additional 4,076 BPD cases and
3,485 healthy controls compared to a previous meta-
analysis of case–control studies [22]. Similar to this previ-
ous meta-analysis, we did not find significant associationslymorphism and bipolar disorders.
Figure 3 Funnel plot of publication bias among the 21 included studies.
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bility either in a combined population or a subgroup of
Oriental patients. However, there was a trend towards sig-
nificant association in Caucasian population (fixed-effects
pooled OR = 1.08, P = 0.05). Subgroup meta-analyses also
showed that the Val allele may be a protective factor for
BP II (fixed-effects pooled OR = 0.88, P = 0.03).Table 3 Descriptive characteristics of included association stu
subtyped bipolar disorders
Study Year Ancestry Diagnostic criteria Pa
Bipolar I disorder
Nakata et al. [39] 2003 Japanese DSM-IV BP
Kunugi et al. [40] 2004 Japanese DSM-IV BP
Lohoff et al. [43] 2005 Caucasian DSM-IV BP
Green et al. [46] 2006 Caucasian DSM-IV BP
Tramontina et al. [48] 2007 Caucasian DSM-IV BP
Xu et al. [54] 2010 Han Chinese DSM-IV BP
Wang et al. [56] 2012 Han Chinese DSM-IV BP
Chang et al. [30] 2013 Han Chinese DSM-IV BP
Bipolar II disorder
Nakata et al. [39] 2003 Japanese DSM-IV BP
Kunugi et al. [40] 2004 Japanese DSM-IV BP
Green et al. [46] 2006 Caucasian DSM-IV BP
Xu et al. [54] 2010 Han Chinese DSM-IV BP
Wang et al. [56] 2012 Han Chinese DSM-IV BP
Chang et al. [30] 2013 Han Chinese DSM-IV BPOur overall finding, that no convincing evidence for as-
sociation between the Val66Met polymorphism and BPD
as a whole, is consistent with a previous meta-analysis re-
ported by Kanazawa et al. [22], which included 11 case–
control designed studies up to February 2006. However,
our overall finding is inconsistent with the result of a
meta-analysis conducted by Fan et al. [15], which includeddies between BDNF gene Val66Met polymorphism and
tient’s phenotype Cases Controls Case Val Controls Val
I 100 190 118 220
I 347 588 412 702
I 621 998 1020 1576
I 864 2100 1418 3404
I 114 137 183 230
I 416 501 451 546
I 281 386 288 436
I 286 349 294 361
II 30 190 34 220
II 172 588 203 702
II 98 2100 159 3404
II 82 501 74 546
II 56 386 53 436
II 681 349 668 361
Figure 4 Forest plot of association between BDNF gene Val66Met polymorphism and subtyped bipolar disorders.
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studies published up to May 2007 and found a modest but
statistically significant association between the Val allele
and BPD susceptibility [15]. Both our analysis and the ana-
lysis of Kanazawa et al. [22] exclusively included case–
control studies. In contrast, the analysis of Fan et al. [15]
included five family-based association studies with a total
of 858 families and a genome-wide association study with
1866 BPD patients and 2932 controls. The inclusion of
different studies in these meta-analyses may explain the
discrepancy among these three meta-analysis studies. It is
well known that BPD is a highly inheritable disorder. In-
clusion of family-based association studies in the meta-
analysis of Fan et al. [15] might increase the probability of
detecting difference between patients and controls.
The finding of insignificant association between the
Val66Met polymorphism and BPD in Oriental population
populations (Chinese, Japanese and Korean populations),Figure 5 Forest plot of comparison between bipolar I disorder and bbut a trend towards significance in Caucasian population
suggest that ethnic heterogeneity may affect the results of
these genetic association studies. Fan et al. [15] reported
that the allele frequencies of the Val66Met polymorphism
in BDNF gene across individual studies and four HapMap
populations (European, Chinese, Japanese and Yoruban
populations) had significant global variations, which raised
concerns of possible population stratification among
case–control studies [15]. A more recent population gen-
etic study found that there were substantial variations in
BDNF coding regions and haplotype frequencies between
58 global populations with the Met allele of Val66Met
ranged from 0-72% frequencies [58]. As previously
pointed out, unless all study participants are from a
homogenous ethnic group, the confounding effect from
different ethnic groups is inevitable [10]. Moreover, con-
trol selection (e.g. healthy control or family control) might
also result in the discrepancy of findings in these geneticipolar II disorder.
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pooled ORs from case–control studies and family-based
studies raised a concern regarding a more generalized
transmission distortion at this locus that is not disease re-
lated [15].
The finding of significant associations between Val66Met
polymorphism and BP II suggests that the strength of asso-
ciation between Val66Met polymorphism and BPD could
depend on the clinical phenotypes or subtypes of BPD such
as with rapid cycling course, early onset, or substance co-
morbidity [10,28,30-32,34,50,55,59]. Interestingly, the Val
allele may have opposite associations with disease suscepti-
bility in different bipolar subtypes. The findings of two pre-
vious studies in Caucasian population (a case–control study
and a family-based study) appeared that the Val allele was
associated with an increased disease risk for rapid-cycling
bipolar disorder (RCBD) [46,60], but this meta-analysis
showed a decreased risk for BP II (especially in Han Chinese
population). However, another family-based association
analysis in Caucasian population did not replicate a sig-
nificant association between the Val66Met polymorphism
and BPD or RCBD. Thus the discrepancy of findings in
these studies may stem from the differences of clinical
phenotypes, ethnic origin and control selection.
Several limitations of this meta-analysis should be con-
sidered. One important limitation is that we only investi-
gated relatively well-studied polymorphic variations in
BDNF gene. Another limitation is that family-based stud-
ies and genome-wide association studies were excluded
due to the heterogeneity of research methods. In a previ-
ous meta-analysis, the pooled OR derived from nine case–
control studies is nominally significant (random-effects
pooled OR = 1.07, P = 0.04), while the pooled OR derived
from five family-based studies increases notably to an OR
of 1.54 (P = 0.000019). Finally, since we primarily designed
the current analysis to demonstrate the potential associ-
ation(s) between Val66Met polymorphism and bipolar
diagnostic boundaries, the association of this polymorph-
ism with other characteristics of BPD such as sex, onset
age, comorbidity, impairment in brain morphology and
function, or treatment response, were not explored.
Conclusions
Taken together, the Val66Met polymorphism in BDNF
gene may be involved in the pathogenesis of BPD by influ-
encing the susceptibility of specific subtypes such as BP II,
but there is no compelling evidence of BDNF gene playing
an important role in susceptibility to BPD across different
ethnicities. The associations observed in current meta-
analysis should be interpreted with caution. Further
large-scale studies with same definitions of phenotypes
and controls in homogenous ethnic groups are warranted
to elucidate the relevance of BDNF gene variations as a
risk factor for BPD (or diagnostic subtypes) susceptibility.Competing interests
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